Albert Bourla

Albert Bourla, CEO of Pfizer since 2019, led the company through a global pandemic and rapidly developed and deployed a vaccine that was eventually taken by millions. That move alone nearly doubled Pfizer’s revenues in fiscal year 2021 to around $81.3 billion. Since then, the company has fallen behind in the weight-loss drug race against competitors like Eli Lilly and Novo Nordisk. A slump in share price since 2022 led to activist-investor hedge fund Starboard Value taking a $1 billion stake in Pfizer this year, though stronger results in the third quarter have buoyed Bourla’s position.